---
title: Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients
nct_id: NCT01049126
overall_status: COMPLETED
sponsor: Precision Therapeutics
study_type: OBSERVATIONAL
primary_condition: Endometrial Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01049126.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01049126"
ct_last_update_post_date: 2011-03-16
last_seen_at: "2026-05-12T06:45:40.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients

**Official Title:** Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx Assay in Cases With Late Stage Endometrial Cancer

**NCT ID:** [NCT01049126](https://clinicaltrials.gov/study/NCT01049126)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 76
- **Lead Sponsor:** Precision Therapeutics
- **Conditions:** Endometrial Cancer
- **Start Date:** 2009-07
- **Completion Date:** 2010-02
- **CT.gov Last Update:** 2011-03-16

## Brief Summary

The purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.

## Detailed Description

This is a multicenter, retrospective chart review study of de-identified drug response marker results and a limited data set of clinical outcome data. Data from approximately 70 cases will be collected from approximately 10 study sites and correlated to the ChemoFx drug response marker results. The outcome of progression free survival will be defined as the period of time between the first dose of chemotherapy following the report of the marker result until clinical progression or death. Objective response will be measured from the first dose of chemotherapy following the report of the marker result until progression or change in therapy. Overall Survival will be measured from the start of chemotherapy to the actual date of death.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Case has an original pathology report showing stage III, IIIa, IIIb, IIIc, IV, IVa, IVb, or recurrent endometrial cancer.
* Case includes a pathology or cytology report from initial diagnosis showing disease of one or more of the following histologic epithelial cell types: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, transitional cell carcinoma, clear cell carcinoma, or adenocarcinoma, not otherwise specified (N.O.S.).
* Case has been identified for pattern of response evaluation.
* Case must have a commercial ChemoFx drug response marker final report.

Exclusion Criteria:

* Cases of patients who were deceased prior to 1 cycle of chemotherapy.
```

## Arms

- **Late stage endometrial cancer**

## Interventions

- **ChemoFx** (OTHER) — Chemoresponse Marker Assay

## Locations (1)

- Precision Therapeutics, Inc., Pittsburgh, Pennsylvania, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.precision therapeutics, inc.|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01049126.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01049126*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*